BioSante considers GVAX makeover following libido gel failure
01 February 2012
Sukaina Virji
Please Login to read the full article.
01 February 2012
Sukaina Virji
sukaina.virji@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- BioSante's female sexual dysfunction drug LibiGel fails to satisfy in Phase III
- BioSante up on early data on GVAX pancreatic cancer vaccine with ipilimumab
- US appeals court upholds Otsuka's patent for Abilify, with protection until 2015
- Pressure mounts on US FDA to address alleged persistent sexual dysfunction with Merck's hair loss drug
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
Today
Le Plaza Hotel, Brussels, Belgium
Today
Diplomat Hotel, Prague, Czech Republic
Today
Business Design Centre, London
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
